Description:GLPG-1690, also known by its chemical name, is a small molecule that has been investigated primarily for its potential therapeutic applications in the treatment of fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). It functions as a selective inhibitor of the enzyme autotaxin, which is involved in the production of lysophosphatidic acid (LPA), a lipid mediator that plays a significant role in cell proliferation, migration, and fibrosis. By inhibiting autotaxin, GLPG-1690 aims to reduce LPA levels, thereby potentially mitigating fibrotic processes in affected tissues. The compound has undergone various phases of clinical trials to evaluate its safety, efficacy, and pharmacokinetic properties. In terms of its chemical structure, GLPG-1690 features specific functional groups that contribute to its biological activity and selectivity. As with many investigational drugs, ongoing research continues to elucidate its full pharmacological profile and therapeutic potential.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![5-Thiazolecarbonitrile, 2-[[2-ethyl-6-[4-[2-(3-hydroxy-1-azetidinyl)-2-oxoethyl]-1-piperazinyl]-8-…](https://static.cymitquimica.com/products/IN/thumb/DA001TG5.jpg)
